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of Biochemistry, Weill Medical College of Cornell University, New York, New YorkABSTRACT Tau is a microtubule associated protein whose aggregation is implicated in a number of neurodegenerative
diseases. We investigate the mechanism by which anionic lipid vesicles induce aggregation of tau in vitro using K18, a fragment
of tau corresponding to the four repeats of the microtubule binding domain. Our results show that aggregation occurs when the
amount of K18 bound to the lipid bilayer exceeds a critical surface density. The ratio of protein/lipid at the critical aggregation
concentration is pH-dependent, as is the binding afﬁnity. At low pH, where the protein binds with high afﬁnity, the critical surface
density is independent both of total lipid concentration as well as the fraction of anionic lipid present in the bilayer. Furthermore,
the aggregates consist of both protein and vesicles and bind the b-sheet speciﬁc dye, Thioﬂavin T, in the manner characteristic of
pathological aggregates. Our results suggest that the lipid bilayer facilitates protein-protein interactions both by screening
charges on the protein and by increasing the local protein concentration, resulting in rapid aggregation. Because anionic lipids
are abundant in cellular membranes, these ﬁndings contribute to understanding tau-lipid bilayer interactions that may be relevant
to disease pathology.INTRODUCTIONNeurofibrillary tangles (NFTs) composed primarily of the
protein tau, are the hallmark of a number of neurodegenera-
tive disorders, including Alzheimer’s disease and the fronto-
temporal dementias. Although it is not clear what precise role
NFTs and other proteinaceous aggregates play in the devel-
opment of disease, the identification of point mutations in tau
that result in hereditary tauopathies suggests a direct connec-
tion between tau misfunction and neurodegeneration (1–5).
Natively, tau is a microtubule-associated protein (6) that
functions to stabilize microtubules and plays a major role in
the establishment of normal neuronal morphology (7–13).
Tau consists of two major segments: an N-terminal, or pro-
jection, domain that projects away from the microtubule
surface, and a C-terminal region, which is responsible for
microtubule binding and assembly (3,7,9,14). Within the
C-terminal half of the protein are repeats of a highly con-
served tubulin binding motif (15). In the adult brain, there
are six isoforms of tau formed by alternative splicing that
differ in the number of tubulin binding repeats (three or
four) and the absence or presence of one or two inserts in
the N-terminus (Fig. 1).
In solution, tau does not show any evidence of adopting
stable secondary or tertiary structure (16). However, NMR
studies of the microtubule binding domain have reported aSubmitted December 16, 2009, and accepted for publication March 2, 2010.
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structure in these regions. It has been hypothesized that this
domain becomes at least partially structured on binding
microtubules (20,21), although much of the N-terminus
appears to remain disordered (11). The assumption of struc-
ture is also relevant to tau pathology, as conformational
changes precede the formation of fibrillar aggregates (22,23)
known as paired helical filaments, PHFs. PHFs, which
further assemble to form NFTs, are rich in b-sheet structure.
Full length tau is highly soluble and does not aggregate
over the course of many days under physiological concentra-
tions and conditions in vitro. To catalyze aggregation reac-
tions on reasonable experimental timescales, negatively
charged molecules are typically used as aggregation inducers
(24–26). Among the most common are polyanions such
as heparin, RNA (25), and fatty acids (27–29). Anionic
micelles, synthetic particles, and lipid vesicles have also
been shown to induce tau fibrillization (22,26,30,31). Lipids
are of particular interest as they are abundant in the cellular
environment and accessible to cytosolic tau. Furthermore,
there is evidence that fibrillar tau aggregates are associated
with the cell membrane (32) and it has been suggested that
interactions between tau and cell membranes may be relevant
for its native function (33–36). Although the significance of
the interactions between tau and lipid membranes has been
shown, they are not well understood. Because binding of
tau to lipid bilayers may have both functional and patholog-
ical manifestations, investigating the nature of this interac-
tion is the focus of our current work.
In this study, we use K18, a fragment of tau that consists
of all four microtubule binding repeats (Fig. 1) (8). Frag-
ments of tau, such as K18, that span the microtubule-binding
domain exhibit accelerated aggregation as compared to the
full length protein (37). In addition, this domain forms thedoi: 10.1016/j.bpj.2010.03.013
FIGURE 1 Tau constructs. The largest isoform (2N4R) is shown to illus-
trate relevant domains of the protein: the projection domain, with amino-
terminal inserts, N1 and N2, and the microtubule binding domain with
repeats R1–R4. Either or both N1 and N2, as well as R2, may be absent
due to alternative splicing. Also shown is the fragment K18 (129 residues,
containing R1–R4). Cys322, which is used for site-specific fluorescent
labeling, is marked with an asterisk (*). All numbering of residues in K18
is based on the 2N4R isoform.
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tive models for the study of tau aggregation. We investigate
both equilibrium binding of K18 to anionic lipid vesicles, as
well as vesicle-induced aggregation of tau. Strikingly, we
find that aggregation occurs at sub-mM protein concentra-
tions when a critical concentration of tau bound to the lipid
bilayer is exceeded, consistent with a nucleated aggregation
mechanism. Furthermore, whereas aggregates are composed
both of protein and vesicles, aggregation does not signifi-
cantly disrupt the lipid bilayer. Our findings suggest that
by screening charges and increasing the local protein con-
centration, the lipid bilayer serves to facilitate protein-protein
interactions favorable for aggregation.MATERIALS AND METHODS
Protein expression and puriﬁcation
The DNA encoding K18 was cloned from the full length protein, 2N4R
(Fig. 1), into a vector containing a cleavable His-tag to facilitate purification.
Purification followed published protocols (39) with a few minor modifica-
tions (see Supporting Materials for details). After checking for purity by
SDS-PAGE, the protein was lyophilized and stored at 20C until use.
Fluorescent labeling of proteins
Site-specific labeling of K18 was achieved using a maleimide-reactive fluo-
rophore on a cysteine residue. K18 contains cysteines at positions 291 and
322 (Fig. 1). Cysteine 291 was mutated to a serine (C291S) using a Quick-
Change Site-Directed Mutagenesis kit (Stratagene, Cedar Creek, TX) to
remove this potential labeling site to ensure that each protein was labeled
with only a single fluorophore. For labeling, ~0.1 mg Alexa 488 maleimide
(Invitrogen, Carlsbad, CA) was incubated with 250 mL of ~100 mM K18, at
room temperature for several hours, then overnight at 4C. The free dye was
removed using two coupled GE HiTrap 5-mL desalting columns. To maxi-
mize the fraction of labeled protein, the protein was passed over Thiopropyl
Sepharose 6B resin (GE Healthcare, Pittsburgh, PA) to separate labeled from
unlabeled protein. The final protein concentration was determined by a modi-
fied Lowry assay (Bio-Rad, Hercules, CA), and the labeling efficiency calcu-
lated using the dye concentration measured by absorbance and the protein
concentration measured by the assay. Throughout the manuscript, we refer
to the C291S mutant as K18, and the labeled construct as K18-AL488.
Although intermolecular disulfide bonds have been shown to accelerate the
aggregation of tau, they are not necessary for aggregation (24). By EM, thefluorophore-labeled tau formed fibrillar aggregates that were indistinguish-
able from those formed by unlabeled tau (data not shown). Monitoring the
emission intensity of K18-AL488 both in the absence and presence of vesi-
cles showed that although there is a slight decrease in the quantum yield of
the Alexa 488 on conjugation to the protein, there is no change in the
quantum yield of K18-AL488 on binding to vesicles.Vesicles
LUVs were prepared from 1:1, 7:3, and 9:1 (molar ratio) PS and PC (Avanti
Polar Lipids, Alabaster, AL). Stock solutions of the lipids were prepared in
chloroform at concentrations of 10 mg/mL and stored at20C for up to six
months. To prepare vesicles, the appropriate volumes of each lipid were
mixed and the chloroform was evaporated under a gentle stream of nitrogen,
followed by overnight dehydration under vacuum. Lipids were rehydrated in
MOPS buffer (20 mM MOPS, 50 mM NaCl, pH adjusted with NaOH) and
extruded 21 times through two stacked 100 nm pore-size membranes in
a Lipofast extruder (Avestin, Ottawa, Canada). The final lipid concentration
of the extruded vesicles was confirmed using a total phosphorus assay
(40,41). For samples requiring fluorescently labeled vesicles, a small amount
(~1:10,000 molar ratio) of fluorescently labeled lipid rhod-PE was incorpo-
rated into the chloroform mixtures before evaporation (LUV-rhod).
Concentrations of lipid are reported as either ‘total’ or ‘accessible’ lipid.
In calculating accessible lipid concentrations, we assumed that the protein
does not insert into the membrane so that it only has access to the outer
leaflet of the bilayer. We estimated that for a ~100 nm diameter vesicle,
~10% more lipid resides in the outer leaflet than in the inner leaflet (42),
and thus calculated accessible lipid concentrations based on measured total
lipid concentrations from the phosphorous assay.FCS
FCS was measured in a lab-built instrument based on an inverted micro-
scope that has been described previously (43,44). Generally, 20 autocorrela-
tion curves were collected at each measurement condition and were analyzed
using MATLAB (The MathWorks, Natick, MA) programs developed in the
lab. All measurements were made at room temperature, which is maintained
at 20.55 0.11C.
By measuring the diffusion times of fluorescent molecules, FCS can be
used to study aggregation and binding of a species diffusing in solution.
For aggregation assays, the amount of lipid was held fixed and protein
was titrated into the vesicle solution. This assay was carried out in two
formats: the first used fluorescently labeled protein and unlabeled vesicles
and the second used unlabeled protein and fluorescently labeled vesicles.
In both cases, aggregation is observed as an irreversible destabilization of
the autocorrelation curve (see Fig. S1 for details). We use the term destabi-
lization to emphasize that evidence of aggregation manifests itself heteroge-
neously but irreversibly (Fig. S1, A and C compared to B and D). A shift to
the right indicating the presence of large fluorescence species is always
observed, but the shape and amplitude of this curve varies greatly from
experiment to experiment. Eventually the aggregated species settle out of
solution, resulting in a complete loss of signal. Although aggregation was
generally observed within the dead time of the experiment, for uniformity,
autocorrelation curves were collected 20 min after addition of protein to
a vesicle solution. This observation time was sufficient for the unambiguous
differentiation of aggregation from the occasional spurious signal due to
inhomogeneities in the vesicle solution, but still well before signal was
lost due to precipitation of the aggregates.
For the aggregation experiments with fluorescently labeled vesicles,
protein concentrations were tested in 50 nM increments, with each sample
freshly prepared in a new sample chamber. The CAC was determined to
be the first concentration at which destabilization of the autocorrelation
curve occurs. The reported CAC value thus has a lower bound of uncertainty
of 50 nM. For example, if the FCS signal is stable at 250 nM protein, but
destabilized at 300 nM protein, the latter value was taken to be the CACBiophysical Journal 98(11) 2722–2730
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and 300 nM.
For binding, the fluorescently labeled protein was held at a fixed concen-
tration whereas the lipid concentration was increased by the addition of vesi-
cles (45). The resulting autocorrelation curves were fit with the following
equation:
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Where, G(t) is the autocorrelation as a function of time t, N is the total
amount of protein added, tD1 and tD2 are the mean diffusion times of free
protein and vesicle bound protein, respectively, q is the ratio of vesicle fluo-
rescence to monomer protein fluorescence, A is the fraction of free protein,
and s is the ratio of the axial to radial dimensions of the observation volume
(46). For our experiments, N and s are constants determined by the amount
of protein present and the instrument optics, respectively. We also fix tD1
and tD2 to values determined by measurements of protein or vesicles alone,
respectively, so that A and q are the only free parameters in the fit.
Imaging of aggregates
Samples containing either LUV-rhod or unlabeled LUVs (50 mM total lipid)
were incubated with 500 nM K18 for 20 min. Half the sample was removed
and ThT was added to the remainder to a final concentration of 25 mM. An
aliquot of each solution was placed in a sample chamber, and then visualized
on the same microscope used for FCS. Images were taken in widefield mode
with a fluorescent lamp for illumination and an EM-CCD camera (Andor
Technology, Belfast, Ireland) set to a 0.2-s acquisition rate for detection.Biophysical Journal 98(11) 2722–2730Filter sets were used to select for either ThT (ex 440/20, em 490/40; Chroma
Technology) or rhodamine (ex 535/30, em 565lp; Chroma Technology)
fluorescence. Control images were taken of samples in the absence of ThT
and/or K18.
ThT binding was also measured by bulk fluorescence. Samples were
prepared as above using unlabeled LUVs. After 20-min incubation the
samples were transferred to cuvettes and ThT fluorescence was measured
on a PTI Quantamaster C-61 fluorimeter (PTI, Birmingham, NJ), with
4-nm slit widths and excitation and emission wavelengths of 450 nm and
485 nm, respectively. Background samples consisted of 25 mM ThT and
LUVs to quantify any interactions between ThT and the lipid bilayer as
well as LUVs and K18 in the absence of ThT to determine whether scat-
tering from the large aggregates affected the signal.
Control experiments using heparin (average MW, 3000 kDa; Sigma,
St. Louis, MO) as an inducer were made for several K18 concentrations.
For each of these experiments, the molar ratio of tau to heparin was
a constant value, 4:1, and 50 mM ThT was present. Fluorimeter settings
were as described above.RESULTS
With the aim of characterizing the interactions between tau
and lipid bilayers, FCS was used as a sensitive measure of
aggregation and binding. Initially, the interaction was moni-
tored as increasing amounts of K18-AL488 were titrated into
a fixed concentration of unlabeled LUVs. At pH 5, binding to
vesicles was observed by an increase in the diffusion time of
K18-AL488 from that of free protein (~450 ms) to that of the
vesicles (~8 ms) (Fig. 2 A). With increasing protein concen-
trations, equilibrium binding was observed. Fits to the auto-
correlation curves yield the diffusion time of the vesicles,FIGURE 2 Aggregation of K18 by LUVs (50 mM lipid).
(A) Autocorrelation curves of vesicle-induced aggregation
of K18-AL488 at pH 5. For comparison, the autocorrela-
tion curve of K18-AL488 in the absence of vesicles is
shown (solid black). On addition of vesicles, the protein
binds and the curves shift to longer times (gray open).
Small shifts to the right are visible at higher protein con-
centrations may be due to an actual increase in the dif-
fusion time of the vesicles when protein is bound, or
simply normal variability in the vesicle sample. When the
CAC is exceeded, the curves are destabilized—they shift
markedly, unpredictably, and irreversibly to the right (solid
gray). Longer incubation times result in complete disap-
pearance of the autocorrelation signal, due to precipitation
of the aggregated species. (B) Autocorrelation curves of
vesicle-induced aggregation of K18 at pH 5. In contrast
to A, K18 is unlabeled and the vesicles are fluorescently
labeled (see Materials and Methods). The vesicle autocor-
relation curves are unaffected by the presence of the pro-
tein (open gray) until the CAC is exceeded, at which
time the curves shift markedly to the right (solid gray),
analogous to the description in A. (C and D) Autocorrela-
tion curves of vesicle-induced aggregation of K18 at pH
6 and pH 7.4, respectively, with labeled vesicles, as in B.
The CAC increases with increasing pH. Comparing the
aggregation curves shown in B–D, illustrates some of the
variability in the observed autocorrelation curves on aggre-
gation. The protein concentrations shown in A–D were
chosen for illustrative purposes and represent only a subset
of the concentrations measured for each condition.
TABLE 1 Comparison of the electrostatic properties and
binding density of K18 and 1:1 PS/PC LUVs as a function of pH
at the CAC
pH
Lacc
(mM)
K18 (nM)
at CAC K18/LUV
Lacc/K18
at CAC
Charge
Lacc (mM)
Charge
K18 (mM)
at CAC
7.4 26.2 725 535 1340 36 13.1 7.5
6.0 26.2 375 5 35 693 70 9.8 5.3
5.0 26.2 267 5 33 493 98 3.3 4.4
5.0 52.4 533 5 88 98
5.0 104.8 12505 25 84
Lacc is the accessible lipid concentration, calculated as described in the Mate-
rials and Methods. In determining the number of K18 molecules per vesicle,
(K18/LUV), we calculated the number of vesicles using the known lipid
concentration and assuming an average vesicle diameter of 100 nm and
the average surface area of the lipid headgroup to be 68 A˚2 resulting in
92,400 lipids per vesicle. The bold numbers in column 5 from this calcula-
tion illustrate that the protein/lipid ratio at the CAC are within experimental
error for several lipid concentrations. The average value of the three pH 5.0
measurements was used in the calculation of protein density at the CAC
described in the Discussion, Lacc/K18 ¼ 93. The charge concentration for
accessible lipid (charge Lacc) assumes the charge per PS to be pH 7.4 ¼ 1,
pH6 ¼ 0.75, and pH 5 ¼ 0.25. Although rhod-PE is expected to carry
a charge of þ1 across the range of pHs used here, because it is used in
very small amounts (1:10,000 molar ratio) relative to the other lipids, we
do not take it into account in our calculations. The charge on K18 was calcu-
lated using Protein Calculator V3.3 (http://www.scripps.edu/~cdputnam/
protcalc.html) and EMBOSS (http://emboss.bioinformatics.nl/cgi-bin/
emboss/iep) programs: pH 7.4 ¼ 10.3, pH 6 ¼ 14.0, and pH 5 ¼ 16.5.
The shaded columns compare the total charge on the vesicles and on the
protein at the CAC in units of concentration.
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Although equilibrium binding dictates that there will always
be a small component of unbound protein, given that the
lower bound of certainty in our measurements, as described
in the Materials and Methods, is 50 nM, in these aggregation
experiments, this amount of unbound protein should be
significantly less than our measurement uncertainty and so
we base our calculations on the assumption that the bound
protein concentration is the total protein concentration. As
the total protein concentration was further increased, the
autocorrelation curves shifted markedly and unpredictably
to the right, as described in the Materials and Methods and
illustrated in Fig. S1. This shift is indicative of the presence
of aggregated fluorescent species (Fig. 2 A). Notably, aggre-
gation was observed with sub-mM K18 concentrations at
pH 5, whereas for pH 6 and pH 7.4, aggregation was not
observed for concentrations as high as several mM (data
not shown). Although FCS measurements on our instrument
become unreliable with >500 molecules/focal volume,
aggregation in the form of destabilization of the autocorrela-
tion curves would still be expected to be easily observable.
To monitor aggregation with an orthogonal probe, the
experiments were repeated using fluorescently labeled vesi-
cles (LUVs-rhod) and unlabeled protein. As with the first
set of experiments, aggregation occurred on reaching a
threshold protein concentration, the critical aggregation
concentration (CAC). In contrast to the first set of experi-
ments, aggregation was observed at sub-mM concentrations
of K18 at all three pH values, with more protein required
with increasing pH (Fig. 2, B–D and Table 1). Initially, stable
autocorrelation curves with a diffusion time corresponding to
that of the vesicles was observed, both in the absence of
protein and with increasing protein concentrations. On
reaching the CAC, destabilization of the autocorrelation
curves indicative of aggregation occurred as observed in
the previous experiment. Notably, the observation of large
fluorescent species by FCS indicated that the vesicles were
associated with the aggregated species. It is important to
emphasize that below the CAC, aggregation was not
observed even for significantly increased observation times.
Below the CAC, vesicle and protein mixtures remained
stable over the course of many hours (Fig. S2), whereas at
the CAC, destabilization was evident within a few minutes.
In the absence of vesicles, concentrations of K18 as high as
10 mM did not show any evidence of aggregation by either
FCS or ThT fluorescence measurements at pH 5, 6, or 7.4
over the timescale of these experiments (data not shown).
To explain differences observed between K18-AL488 and
unlabeled K18 at pH 6 and 7.4, we measured the affinity of
K18-AL488 for the lipid bilayer by titrating unlabeled vesi-
cles into a fixed concentration of labeled protein. For these
experiments, ~20 nM protein was used to ensure that even
at the lowest lipid concentrations, the protein/lipid ratio
remained well below aggregation conditions as described
above. We found that at pH 5 K18-AL488 binds to the vesi-cles with an apparent affinity, K, (in terms of lipid concentra-
tion) in the low mM, whereas at pH 6 and 7.4, the apparent K
is shifted over three orders of magnitude to the mM range
(Fig. 3). Although the binding affinity may be expected to
change with pH due to titration of groups both on the protein
and on the lipids, such a dramatic shift suggests that at higher
pH the interaction between the protein and the lipid bilayer is
perturbed, most likely by the presence of the fluorophore on
the protein that carries a charge of 2 at all pHs measured.
The agreement between the results obtained for aggregation
experiments on K18-AL488 and unlabeled K18 at pH 5 indi-
cated that for this higher affinity interaction the presence of
the fluorophore had significantly less of an effect.
To assess what factors, in addition to pH, influence the
CAC, we repeated the experiments at pH 5 using different
lipids concentrations and different ratios of PS/PC. The lipid
to protein ratio at the CAC was found to be independent of
the total amount of lipid present (Table 1, bold values in
column 5), suggesting that the local concentration of protein
at the vesicle surface was an important factor in initiating
aggregation. Interestingly, increasing the relative amount
of PS to PC from 1:1 to 7:3, and 9:1, had little effect on
the measured CAC, ~250 nM protein for 50 mM total lipid
(data not shown), despite the significant increase in binding
affinity with increasing PS ratio (Fig. 3). From our experi-
ments with labeled protein, we know that the majority of
the protein is bound to the vesicles at the CAC (Fig. 2 A),Biophysical Journal 98(11) 2722–2730
FIGURE 4 Images of aggregates formed by K18 and LUVs. (A and B)
Samples imaged in the absence of ThT only show the presence of aggregates
when the rhodamine filter set is used, evidence that there is no excitation of
the rhodamine fluorophore with the ThT filter set. The image shows aggre-
gates composed of LUV-rhod that are as large as several microns. (C and D)
When 25 mM ThT is added to the samples before imaging, ThT positive
aggregates colocalize with the LUV-rhod aggregates indicating that the
K18 is associated with the aggregated lipids and capable of binding ThT
in the characteristic manner associated with pathological aggregates.
FIGURE 3 Binding of K18-AL488 to 1:1 PS/PC LUVs as a function of
pH. Below the CAC, K18 binds vesicles without aggregating. The large shift
in the apparent affinity between pH 5 (open circles) and pH 6 and 7.4 (open
squares and triangles, respectively), suggests that at higher pH, the presence
of fluorescent label may interfere with binding. Most points on the binding
curves are the average of three independent measurements and the error
bars are the standard error of these measurements. There are a few points
obtained from single measurements that are also included in the curves;
these points do not have any error bars associated with them. Lines are
drawn to guide the eye. For comparison, the fraction K18 bound to vesicles
composed of 7:3 (gray solid circle) and 9:1 (black solid circle) ratios of
PS/PC for 2 mM total lipid are plotted (gray shading on plot). The amount
of protein bound increases with the fraction of PS in the lipid bilayer.
2726 Elbaum-Garﬁnkle et al.suggesting that the surface density of protein on aggregation
is the same for all three vesicle compositions. We thus con-
clude that although increasing the fraction of anionic lipid
increases the binding affinity of K18 for the vesicles, the
protein density on the vesicle surface at the CAC is unaf-
fected by the increase in anionic charge of the vesicle.
To probe the structure of K18 in the aggregates, images
of aggregated K18/LUV-rhod samples were taken with and
without ThT (Fig. 4). In the absence of ThT, aggregated
LUVs-rhod were visible (Fig. 4, A and B) as expected from
the FCS measurements that indicated that the vesicles
were incorporated into the aggregated species. On addition
of ThT, the aggregates observed with the ThT filter set colo-
calized with those seen using the rhodamine filter set (Fig. 4,
C and D), suggesting that the associated protein was capable
of binding ThT in a manner characteristic of PHFs. In the
absence of K18, there was no evidence of aggregated species
in the samples (Fig. S3, A and B). Measurements of ThT
fluorescence in a fluorimeter show that ThT does not interact
strongly with the vesicles alone and that K18/vesicle
aggregates give rise to a ThT signal above the background
(Fig. S3 E). As a control, heparin induced aggregation of
K18 was measured at 500 nM, comparable to concentrations
used in our FCS experiments (Fig. S3F). The ThT signal over
the course of 1 h was only slightly greater than background.
Finally, leakage assays based on an encapsulated dye and
quencher were used to test if tau aggregation compromised
lipid bilayer integrity (see Supporting Materials for details).
Under conditions where aggregation is readily observable byBiophysical Journal 98(11) 2722–2730FCS for K18 (Fig. 2, A and B)—pH 5, 50 mM lipid, and
500 nM protein—no increase in fluorescence signal was
observed (Fig. S4), indicating that the lipid bilayer remained
intact.DISCUSSION
Tau is a microtubule binding protein that has been shown to
interact with cellular membranes in vivo (33–36). We there-
fore sought to assess the capacity of tau to interact with lipid
bilayers under conditions of physiological and pathological
relevance. The primary results of our experiments are: i),
vesicle induced aggregation of tau is pH dependent and
occurs when a critical concentration of protein is bound to
a vesicle; ii), the aggregate formed is composed of both pro-
tein and vesicles and binds ThT in a characteristic manner;
and iii), the lipid bilayer integrity is not affected by aggrega-
tion. Below, we interpret our results by considering several
properties of tau that are influenced by its interactions with
lipid vesicles.
Aggregated species
The data presented in this study shows that anionic vesicles
are potent inducers of tau aggregation. Notably, aggregation
Lipid-Induced Aggregation of Tau 2727occurs rapidly on reaching a CAC (Table 1), consistent with
the nucleated aggregation mechanism that has been proposed
for tau (23,47,48). At pH 5, where we can use fluorescently
labeled tau to determine that most of the total protein in solu-
tion is bound to the vesicles (Fig. 2 A), the CAC can be trans-
lated directly to a critical surface density. However, at pH 6
and 7.4, where the fluorescent probe seems to interfere with
vesicle binding, we do not have a direct probe of amount of
protein bound and thus can only monitor the total amount of
protein present when aggregation is observed.
FCS has been used by a number of groups, including our
own, to study stable binding interactions between proteins
and peptides and vesicles (45,49,50,52,53), although to our
knowledge, this is the first time it has been used to study
the role of vesicle interactions in amyloid formation. In con-
trast to ThT fluorescence, FCS serves as a direct probe of the
interaction between tau and its inducer. Moreover, because
the vesicles are large particles relative to the protein, a signal
is observable by FCS under conditions where protein aggre-
gation is difficult to observe by ThT binding alone, notably
at the sub-mM protein concentrations used in this study
(Fig. S3, E and F). FCS shows that the aggregates are com-
posed both of vesicles and protein (Fig. 2) and imaging of
the aggregated species in the presence of ThT (Fig. 4 and
Fig. S3) shows aggregated species bind ThT. ThT binding
is associated with the presence of b-sheet structure in PHFs,
as well as in prefibrillar intermediates (22,23). Our findings
support an earlier study at much higher protein concentra-
tions that found that vesicle induced aggregation of tau
resulted in aggregates that were morphologically similar to
PHFs formed under other conditions (30).Electrostatics
Anionic vesicles cause K18 to aggregate at very low
(<1 mM) protein concentrations, requiring additional protein
with increasing pH (Table 1). K18 contains a number of
histidines that are expected to be neutral at physiological
pH but positively charged at pH 5, raising the net positive
charge of the protein with decreasing pH, and thereby
increasing its affinity for anionic vesicles. However, lower-
ing the pH also has the effect of decreasing the negative
charge of vesicles by titrating a carboxyl group on the PS
headgroup, an effect that should serve to reduce the attrac-
tion of positively charged K18 for the vesicles. Although
determining the charge at a bilayer surface depends on
numerous factors, including the ionic strength of the buffer
and the mole fraction of PS present (54), these factors are
invariant over our measurement conditions using 1:1 PS/
PC vesicles. Because our analysis below is dependent on
orders of magnitude calculations of liposome charge, our
findings are not markedly altered by small shifts to the values
used in our calculations (see Table 1).
Based on our measurements using labeled vesicles and
unlabeled K18, we calculated overall charge of the proteinand the lipids at the CAC of tau to determine the number
of lipids per protein binding site (see Table 1 caption).
Table 1 shows that at the CAC, the absolute value of the
protein charge and the accessible charge on the vesicles are
of the same order of magnitude, although the vesicle charge
is of a greater absolute value than the K18 charge at pH 6 and
7.4, such that there is always sufficient negative charge to
neutralize the positively charged proteins, whereas at pH 5,
the absolute charge on the protein and accessible lipid are
almost identical (shaded columns in Table 1). This suggests
that charge neutralization plays a role in the vesicle-induced
aggregation of K18. Negatively charged molecules used are
commonly for in vitro studies of tau aggregation, and it is
generally thought they function as inducers by neutralizing
the positive charges of the MT binding domain (22,30).
Lending support to this hypothesis is the observation that
induced tau aggregation is generally pH dependent (55,56)
and it has been suggested that a change in pH modulates
the affinity of tau for its inducer (24). Our pH data, which
shows that with increasing pH there is both a reduced binding
affinity and as well as an increase in the amount of protein
required for aggregation to occur (Fig. 2, B–D), qualitatively
support this explanation. However, we also find that although
K18 binds with an increased affinity to vesicles containing
a larger fraction of anionic lipids, the CAC is independent
of the total fraction of anionic lipid over the range we tested
(Fig. 3). Along with the differences we observe in binding
and aggregation at different pHs, this suggests that electro-
static shielding is not the only relevant factor.Surfaces
In addition to its role in mediating electrostatic interactions
between tau proteins, the lipid bilayer also provides a surface
that may facilitate protein-protein associations by increasing
their local concentration. In their studies of fatty acid induced
aggregation of tau, Chirita et al. (30) found that fatty acids
were in micellar form when capable of promoting aggrega-
tion and proposed that the general induction mechanism
for anionic micelles is by concentrating tau at their surface.
Although heparin is not known to form micelles, it is a poly-
mer and it has been proposed that a single heparin can coor-
dinate several tau molecules, resulting in a local region of
high protein concentration (57).
Because the majority of our data is at pH 5, we will
consider this data for further calculations. At the CAC,
there are ~93 accessible lipids per protein (determined as
described in Table 1) independent of total protein and lipid
concentration. To calculate the maximum area that a single
protein could occupy on the lipid bilayer, we model K18
binding as a random coil. By FCS measurements of the dif-
fusion time of K18-AL488 in solution, we calculate a hydro-
dynamic radius of ~36 A˚, which is in reasonable agreement
both with what is predicted for a highly denatured protein
(58) as well as with published values of the radius of gyrationBiophysical Journal 98(11) 2722–2730
2728 Elbaum-Garﬁnkle et al.of K18 (59). The corresponding area on the bilayer occupied
by random coil K18 is ~4100 A˚2. Using the value of 68 A˚2 for
the area of a lipid headgroup in a fluid bilayer (42), the result-
ing number of lipids in one leaflet of the bilayer needed to
accommodate a single K18 molecule is ~60. Because it is
known that tau becomes partially helical on binding to lipid
vesicles (21), thereby reducing its bilayer footprint, we can
reasonably assume that the actual number of lipids required
for binding is <60. Our measured value of 93 lipids is ~1.5
times greater than this maximum value, indicating that aggre-
gation is unlikely to be triggered by relatively close packing of
the protein on the bilayer surface. This modeling does not
consider the case where tau may actually insert into the
bilayer, but given that our leakage measurements do not indi-
cate significant perturbation of the bilayer on aggregation
(Fig. S4) and that polystyrenemicrospheres, which are imper-
meable to protein insertion, are also capable of promoting tau
aggregation (23), this assumption is likely justified.
At pH 5, where essentially all the protein is bound before
aggregation (Fig. 2 A), the CAC can be directly translated to
a surface density. Assuming that a single vesicle (diameter¼
100 nm) has a surface area ~31,400 nm2, and that the protein
bound to the vesicle is localized to the surface in a layer that
is the thickness of an a-helix (5 A˚) plus a hydration layer
(5 A˚), the volume at the vesicle surface is ~31,400 nm3/
vesicle or 3.14  1020 L/vesicle. The number of proteins
bound per vesicle at the CAC is ~493 (Table 1) or ~8.19 
1022 moles protein/vesicle. Thus the concentration of pro-
tein at the vesicle surface is ~26 mM, or almost five orders
of magnitude greater than the bulk solution concentration.
Even assuming a hydration layer 10 times as thick (50 A˚)
yields a surface concentration ~5 mM. This calculation illus-
trates how effectively the vesicle raises the local protein
concentration at the bilayer interface. In a cellular context,
such a mechanism may explain how normal physiological
concentrations of tau may be induced to aggregate.Physiological role for lipids in aggregation
There is significant evidence, both in vitro and in vivo, that
interactions between tau and the lipid bilayer may be of
importance. EM images of vesicle induced tau aggregates
found that a fraction of the filaments were associated with
a vesicle at the terminus of the fiber (30). It has been sug-
gested that PHF assembly in the cell may begin at the plasma
membrane (34,60) and lipids have been found in the paired
helical filaments purified from brains of Alzheimer’s patients
(61). Interactions with cellular membranes may also be rele-
vant to the normal function of tau. It has also been proposed
that one of the major roles of the N-terminal projection
domain may be to mediate interactions with specific compo-
nents in the cellular membrane (33,62,63). More relevant to
our study is evidence that the microtubule binding repeats
themselves may bind nonspecifically to lipid surfaces in
the cell (64,65). Whereas our studies used vesicles composedBiophysical Journal 98(11) 2722–2730of at least 50% PS, which is significantly higher than the esti-
mated <20% PS found in plasma membranes (66) increased
levels of PS are found in neural membranes of patients with
Alzheimer’s disease (67), and in vitro studies have shown
that PS vesicles can effectively compete with microtubules
for binding to tau (65).CONCLUSIONS
Our results show that anionic lipid vesicles are extremely
effective at promoting aggregation of the microtubule bind-
ing domain of tau, and are capable of inducing aggregation at
sub-mM protein concentrations. Moreover, the aggregated
species formed consist of both protein and intact lipid vesi-
cles. We propose that the mechanism of induction of aggre-
gation of tau by lipid vesicles occurs through a combination
of charge neutralization and providing a platform for favor-
able protein-protein interactions.SUPPORTING MATERIAL
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